Pharmaceutical companies intellectual property and the global aids epidemic

In situations where there is a health epidemic, this is problematic because it offers the medication to select groups within society. AIDS is a global problem. Should pharmaceutical companies distribute drugs at low cost in third world countries? What are the arguments by NGOs and others for a differential treatment?

Still, the method of implementation at the national or regional trade level of TRIPS can cause problems. Although the tentative WTO agreement would appear to allow such production under limited circumstances, former U.

Pharmaceutical Companies, Intellectual Property, and the Global Aids Epidemic

On September 5,GlaxoSmithKline announced an additional price cut for antiretroviral drugs and malaria drugs for poor countries. They are unable to provide sanitation and to buy drugs for those who cannot afford them. When lesser known companies duplicate their products and sell it at lower prices, it does hamper the innovation atmosphere.

Companies agreed to invest further in research and development of new HIV-related medicines adapted to resource-limited settings. I know of no enemy in war more insidious or vicious than AIDS, an enemy that poses a clear and present danger to the world.

In these developing countries, such as in the sub-Saharan region of Africa, there is widespread poverty and few are very highly educated.

Drug prices had fallen significantly, but not low enough for everyone. AIDS is an epidemic in third world countries. While offering, these drugs in select regions at lower costs to realize a profit.

Pharmaceutical Companies Intellectual Property and the Global AIDS Epidemic&nbspResearch Paper

The amount of money that was sent to developing countries for the purposes of spreading prevention was very small, as the case states. Those less concerned with the patents for these drugs are concerned about the alarming AIDS statistics, which clearly demonstrate the fact that there is an AIDS epidemic in some of the poorest countries in the world.

Generic drug manufacturers have lowered the costs of some much-needed drugs to developing countries, but often new drugs were still priced much higher than old treatments, and are hence unavailable in many of the countries with the most need. NGOs, such as Doctors Without Borders, were expected to push for optimizing use of scarce funds by deploying Global Fund allocations for purchase of generics only.

To encourage individuals and companies to engage in these kinds of activities means that there must be higher profit margins. The reason why, is because they will often go around the world and extract different natural resources from various area to create numerous treatment options.

In your opinion, do you think this is an appropriate change in policy, or a dangerous precedent? Once this occurs, it will cause the price for all available drugs to be limited to the wealthy and privileged who can afford these costs.

The WTO group should ask questions during the hearing. This is imperative for people to notice as they look for a one stop solution to the AIDS crisis. In Junethe WTO extended the transition period during which least-developed countries LDCs had to provide patent protection for pharmaceuticals.

Norvir is a key ingredient in most AIDS treatment cocktails. Doctors Without Borders spoke out in March against what it calls the standard practice of drug companies marketing less adapted drugs to African, Asian, and Latin American countries, while reserving new and improved drugs for more wealthy countries.

The administration informed the South African government it would not object to issuance of compulsory licenses for essential drugs provided this was done within WTO guidelines. Some felt that if the pharmaceutical industry really wanted to make its products available it should drop its lawsuit against the South African government.

AIDS deaths were halved between and Nonetheless, the day after the agreement was announced, the government of Brazil said it would publish a decree authorizing imports of generic versions of patented AIDS drugs that the country said it could no longer afford to buy from multinational pharmaceutical companies.

Witty recalled that as recently asit was extremely difficult to conduct clinical trials in HIV because patients rarely lived long enough to complete studies. However, there are those individuals that believe if the drug companies engage in these kinds of activities it will erode their profit margins.

The second one is: Drug discovery is a long, expensive, and uncertain process. The new company will have 11 drugs on the market and a further six in clinical development. In the U.

Doctors Without Borders worker Dr. In Marcha consortium of religious investors forwarded shareholder resolutions at four top drug makers, asking the companies to assess how much charity work they are doing for HIV and AIDS in developing countries and to estimate how much the epidemic could affect their businesses.

They also have lower levels of education, and therefore people are less aware of measures needed to prevent the spread of disease. This will cause the number of supplies to decrease. The probability of the product reaching to its target audience is next to zero. What are the principal arguments of pharma companies who oppose making exception to IPR laws for developing countries?Pharmaceutical Companies, Intellectual Property, and the Global AIDS Epidemic.

In Augustafter heavy lobbying from nongovernmental organizations (NGOs) such as Doctors Without Borders, the U.S. pharmaceutical industry finally dropped its opposition to relaxation of the intellectual property rights (IPR) provisions under World Trade. IBUS - International Management Pharmaceutical Companies, Intellectual Property, and the Global AIDS Epidemic Analysis While this case is literally full of negative aspects, we will only focus on the main points for both arguments/5(1).

pharmaceutical companies,intellectual property,and the global aids epidemic 1. pharmaceutical companies,intellectual property,and the global aids epidemic by jahnab bhaskar rakesh rahul tomy 2. Pharmaceutical Companies, Intellectual Property, and the Global AIDS Epidemic For this case study, six questions had been asked.

The first one is: Should pharmaceutical companies distribute drugs at low cost in third world countries? Pharmaceutical Companies, Intellectual Property, and the Global AIDS Epidemic Did you know?

It typically takes years and $ million. Pharmaceutical Companies, Intellectual Property, and the Global AIDS Epidemic Analysis While this case is literally full of negative aspects, we .

Download
Pharmaceutical companies intellectual property and the global aids epidemic
Rated 3/5 based on 26 review